𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Modelling for cost-effectiveness analysis

✍ Scribed by Louise B. Russell


Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
83 KB
Volume
18
Category
Article
ISSN
0277-6715

No coin nor oath required. For personal study only.

✦ Synopsis


A model creates the framework for a cost-e!ectiveness analysis, allowing decision makers to explore the implications of using an intervention in di!erent ways and under di!erent conditions. To serve its purpose a model must produce accurate predictions and allow for substantial variation in the factors that in#uence costs and e!ects. This paper considers three aspects of modelling: validating e!ectiveness estimates; modelling costs; and the implications of common statistical forms. Validation procedures similar to those for e!ectiveness estimates are proposed for costs. Modellers need to pay more attention to ensuring that the pathway of events described by a model represents costs as well as it does e!ects. Modellers can also help improve the epidemiological and clinical research on which cost-e!ectiveness analyses depend by showing the implications for resource allocation of the statistical forms conventionally used in these "elds.


πŸ“œ SIMILAR VOLUMES


An Effective Approach for Landfill Closu
✍ Ahmed Fouda; Brian Jankauskas; Dan Martin; Thomas Lewis πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons βš– 253 KB

## Abstract This article presents a design approach that has been developed and used on actual projects for a landfill closure plan, including a slurry wall, a leachate collection system, and cap design. A relationship exists between the cost of each of these landfill closure constituents and their

Surrogates, meta-analysis and cost-effec
✍ Neil Hawkins; Gerry Richardson; Alex J Sutton; Nicola J Cooper; Chris Griffiths; πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 359 KB

## SUMMARY Estimates of cost‐effectiveness analyses are typically obtained either directly from β€˜trial’ based analyses or indirectly via surrogate endpoints in β€˜model’ based analyses. Data from clinical trials that include both surrogate and final endpoints can be used in a joint analysis that comb